RESUMO
Canine histiocytic sarcoma (HS) represents a malignant neoplastic disorder often with a rapid and progressive clinical course. A better understanding of the interaction between tumor cells and the local microenvironment may provide new insights into mechanisms of tumor growth and metastasis. The influence of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) on tumor angiogenesis, invasion and metastasis has been detailed in previous studies. In addition, inflammatory cells infiltrating neoplasms especially tumor associated macrophages (TAM) may contribute significantly to tumor progression. Due to the high variability of spontaneously occurring canine HS, standardized models are highly required to investigate tumor progression and interaction with its microenvironment. Therefore, the present study comparatively characterized the intratumoral macrophage infiltration as well as the expression of MMP-2, MMP-9, MMP-14 and TIMP-1 in spontaneous canine HS and its murine model. In spontaneous canine HS, scattered MAC 387-positive macrophages were randomly found in tumor center and periphery, whereas tumor cells were negative for this marker. Interestingly, quantitative analysis revealed that MMPs and TIMP-1 were mainly expressed at the invasive front while tumor centers exhibited significantly reduced immunoreactivity. Similar findings were obtained in xenotransplanted HS. Interestingly, murine tumor associated macrophages (TAM), characterized by Mac3 expression (CD107b/LAMP2), which was not present in xenotransplanted histiocytic sarcoma cells, strongly express MMPs and TIMP-1. In addition, MMPs are known to regulate angiogenesis and a positive correlation between MMP-14 expression and microvessel density was demonstrated in xenotransplanted histiocytic sarcomas. Summarized similar findings with respect to MMP and TIMP distribution and the role of macrophages in spontaneously-occurring and xenotransplanted HS indicate the high suitability of this murine model to further investigate HS under standardized conditions. Moreover results indicate that MMP expression contributes to tumor progression and invasion and TAMs seem to be major players in the interaction between neoplastic cells, the microenvironment and vessel formation indicating that therapeutic approaches modulating TAM associated molecules might represent promising future treatment options.
Assuntos
Doenças do Cão/enzimologia , Sarcoma Histiocítico/veterinária , Metaloproteinases da Matriz/biossíntese , Animais , Modelos Animais de Doenças , Doenças do Cão/imunologia , Cães , Feminino , Sarcoma Histiocítico/enzimologia , Sarcoma Histiocítico/imunologia , Linfócitos do Interstício Tumoral , Proteína 2 de Membrana Associada ao Lisossomo/metabolismo , Macrófagos/imunologia , Masculino , Camundongos , Transplante de Neoplasias , Receptores Depuradores Classe A/metabolismo , Inibidor Tecidual de Metaloproteinase-1/metabolismo , Transplante HeterólogoRESUMO
Histiocytic sarcoma in humans is an aggressive orphan disease with a poor prognosis as treatment options are limited. Dogs are the only species that spontaneously develops histiocytic sarcoma with an appreciable frequency, and may have value as a translational model system. In the current study, high-throughput drug screening utilizing histiocytic sarcoma cells isolated from canine neoplasms identified these cells as particularly sensitive to a MEK inhibitor, trametinib. One of the canine cell lines carries a mutation in PTPN11 (E76K), and another one in KRAS (Q61H), which are associated with the activation of oncogenic MAPK signaling. Both mutations were previously reported in human histiocytic sarcoma. Trametinib inhibited sensitive cell lines by promoting cell apoptosis, indicated by a significant increase in caspase 3/7. Furthermore, in vitro findings were successfully recapitulated in an intrasplenic orthotopic xenograft mouse model, which represents a disseminated aggressive form of histiocytic sarcoma. Mice with histiocytic sarcoma xenograft neoplasms that were treated with trametinib had significantly longer survival times. Target engagement was validated as activity of ERK, downstream of MEK, was significantly downregulated in neoplasms of treated mice. Additionally, trametinib was found in plasma and neoplastic tissues within projected therapeutic levels. These findings demonstrate that in dogs, histiocytic sarcoma may be associated with a dysfunctional MAPK pathway, at least in some cases, and may be effectively targeted through MEK inhibition. Clinical trials to test safety and efficacy of trametinib in dogs with histiocytic sarcoma are warranted, and may provide valuable translational information to similar diseases in humans. Mol Cancer Ther; 17(11); 2439-50. ©2018 AACR.
Assuntos
Sarcoma Histiocítico/tratamento farmacológico , Sarcoma Histiocítico/enzimologia , Quinases de Proteína Quinase Ativadas por Mitógeno/antagonistas & inibidores , Modelos Biológicos , Terapia de Alvo Molecular , Pesquisa Translacional Biomédica , Animais , Apoptose/efeitos dos fármacos , Ciclo Celular/efeitos dos fármacos , Linhagem Celular Tumoral , Proliferação de Células/efeitos dos fármacos , Cães , Regulação para Baixo/efeitos dos fármacos , Feminino , Sarcoma Histiocítico/patologia , Fígado/efeitos dos fármacos , Fígado/patologia , Sistema de Sinalização das MAP Quinases/efeitos dos fármacos , Camundongos Endogâmicos NOD , Camundongos SCID , Quinases de Proteína Quinase Ativadas por Mitógeno/metabolismo , Fosfatidilinositol 3-Quinases/metabolismo , Proteínas Proto-Oncogênicas c-akt/metabolismo , Piridonas/farmacologia , Piridonas/uso terapêutico , Pirimidinonas/farmacologia , Pirimidinonas/uso terapêutico , Análise de Sobrevida , Regulação para Cima/efeitos dos fármacos , Ensaios Antitumorais Modelo de XenoenxertoRESUMO
The histiocytoses are rare tumors characterized by the primary accumulation and tissue infiltration of histiocytes and dendritic cells. Identification of the activating BRAFV600E mutation in Erdheim-Chester disease (ECD) and Langerhans cell histiocytosis (LCH) cases provided the basis for the treatment with BRAF and/or MEK inhibitors, but additional treatment options are needed. Twenty-four cases of neoplastic histiocytic diseases [11 extrapulmonary LCH, 4 ECD, 4 extranodal Rosai-Dorfman disease (RDD), 3 follicular dendritic cell sarcoma (FDCS), 1 histiocytic sarcoma (HS) and 1 blastic plasmacytoid dendritic cell neoplasm (BPDCN)] were analyzed using immunohistochemical and mutational analysis in search of biomarkers for targeted therapy. BRAF V600E mutations were detected in 4/11 LCH and 4/4 ECD cases. A pathogenic PTEN gene mutation and loss of PTEN protein expression were identified in the case of HS. Increased expression of PD-L1 (≥2+/≥5%) was seen in 3/4 ECD, 7/8 LCH, 3/3 FDCS and 1/1 HS, with overall 81% concordance between 2 antibodies used in the study (SP142 vs. MAB1561 clone). These results show for the first time significant expression of the PD-L1 immune checkpoint protein in these disorders, which may provide rationale for addition of immune check-point inhibitors in treatment of disseminated and/or refractory histiocytoses.
Assuntos
Antígeno B7-H1/análise , Sarcoma de Células Dendríticas Foliculares/metabolismo , Células Dendríticas/química , Doença de Erdheim-Chester/metabolismo , Histiócitos/química , Sarcoma Histiocítico/metabolismo , Histiocitose de Células de Langerhans/metabolismo , Histiocitose Sinusal/metabolismo , Mutação , Proteínas Proto-Oncogênicas B-raf/genética , Adolescente , Adulto , Idoso , Criança , Pré-Escolar , Análise Mutacional de DNA , Sarcoma de Células Dendríticas Foliculares/enzimologia , Sarcoma de Células Dendríticas Foliculares/genética , Sarcoma de Células Dendríticas Foliculares/patologia , Células Dendríticas/enzimologia , Doença de Erdheim-Chester/enzimologia , Doença de Erdheim-Chester/genética , Doença de Erdheim-Chester/patologia , Feminino , Marcadores Genéticos , Histiócitos/enzimologia , Histiócitos/patologia , Sarcoma Histiocítico/enzimologia , Sarcoma Histiocítico/genética , Sarcoma Histiocítico/patologia , Histiocitose de Células de Langerhans/enzimologia , Histiocitose de Células de Langerhans/genética , Histiocitose de Células de Langerhans/patologia , Histiocitose Sinusal/enzimologia , Histiocitose Sinusal/genética , Histiocitose Sinusal/patologia , Humanos , Imuno-Histoquímica , Masculino , Pessoa de Meia-Idade , PTEN Fosfo-Hidrolase/análise , PTEN Fosfo-Hidrolase/genética , Adulto JovemRESUMO
Two cases of leukemic malignant histiocytosis had similar morphologic and enzyme histochemical findings. Large blasts with low nuclear/cytoplasmic ratios, occasional azurophilic granules, and immature nuclei with nucleoli were seen in peripheral blood and bone marrow smears. Case 1 had occasional erythrophagocytosis, while in Case 2 it was rare. They were peroxidase negative, and very strongly positive by alpha-naphthyl butyrate esterase stain, the latter being inhibited by sodium fluoride. Acid phosphatase stains were also very strongly positive and were inhibited with tartaric acid. They were also stained granularly with PAS. Surface marker analysis revealed myeloid surface antigens, CD11+, CD13+ and HLA-DR+ in Case 1, and CD11+, CD13+, CD33+ and HLA-DR+ in Case 2. Immunoperoxidase stains of bone marrow biopsies revealed that lysozyme was positive in both cases. S-100 protein was strongly positive in Case 1, but weakly so in the skin tumor and negative in the bone marrow of Case 2. Electron microscopy showed both cases to be myeloperoxidase negative and rich in cytoplasmic organelles, such as lysosomes, mitochondria, and endoplasmic reticuli. Nuclei were irregularly shaped and nucleoli were present in virtually all the cells. These findings suggest that the malignant histiocytes in these two cases derive from bone marrow macrophages, and S-100 protein can also be detected in monocyte-macrophage derived histiocytes.
Assuntos
Biomarcadores Tumorais/análise , Sarcoma Histiocítico/patologia , Adenocarcinoma , Adulto , Idoso , Antígenos de Neoplasias/análise , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Coriocarcinoma/tratamento farmacológico , Diagnóstico Diferencial , Feminino , Sarcoma Histiocítico/diagnóstico , Sarcoma Histiocítico/enzimologia , Sarcoma Histiocítico/imunologia , Humanos , Neoplasias Renais , Leucemia Monocítica Aguda/diagnóstico , Leucopenia/complicações , Masculino , Proteínas de Neoplasias/análise , Neoplasias Primárias Múltiplas , Trombocitopenia/complicações , Neoplasias Uterinas/tratamento farmacológicoRESUMO
Tumor tissues from 36 autopsy cases of malignant histiocytosis were collected for studying the distribution of lysozyme (LyS), alpha 1-antichymotrypsin (ACT) and alpha 1-antitrypsin (AT) by double peroxidase anti-peroxidase staining. The positive rates of LyS, ACT and AT were 97.14%, 91.67% and 77.78% respectively. LyS was seen mainly in the well-differentiated histiocytes. No phagocytosis was found in these cells. ACT existed in some well-differentiated histiocytes in which phagocytosis was often seen. A few atypical histiocytes also showed positive reaction to ACT. AT-positive cells were mainly atypical histiocytes and atypical multinuclear-giant-histiocytes. This study not only confirms that the tumor cels of malignant histiocytosis originate from histiocytes, but also indicates that staining of LyS, ACT and AT is useful for classification and differential diagnosis of tumor cells in malignant histiocytosis.
Assuntos
Sarcoma Histiocítico/enzimologia , Muramidase/metabolismo , alfa 1-Antiquimotripsina/metabolismo , alfa 1-Antitripsina/metabolismo , Humanos , Imuno-HistoquímicaRESUMO
This report is a case of histiocytic sarcoma (HS), in which tumor cells consist of two immunohistopathologically distinct populations (A) oval CD68+lysozyme+CD163- cells and (B) abundant cytoplasm or spindle-shaped CD68+lysozyme-CD163+ cells. Cervical lymph node was infiltrated mainly by population (A), where chemotherapy was quite effective. On the other hand, vast majority of infiltrated tumor cells in the hilar lymph node belonged to population (B), in which the cells were resistant to chemo-radiotherapy. Considering the poor prognosis of HS, the expression of CD163 could be a marker for resistance to chemo-radiotherapy. It is also notable that CD163-negative stage of HS may exist and still be reactive for the treatment.
Assuntos
Sarcoma Histiocítico/imunologia , Sarcoma Histiocítico/patologia , Idoso , Antígenos CD/análise , Antígenos de Diferenciação Mielomonocítica/análise , Forma Celular , Evolução Fatal , Sarcoma Histiocítico/enzimologia , Sarcoma Histiocítico/terapia , Humanos , Linfonodos/química , Linfonodos/metabolismo , Linfonodos/patologia , Masculino , Muramidase/análise , Receptores de Superfície Celular/análiseRESUMO
Immunohistochemically, the presence of lysozyme (LZ) has been detected by the antibody against human LZ in cytoplasm of cells from granulomatous and histiocyte-proliferative skin diseases. To detect LZ in these cells morphologically, I have done electron microscopic observations of the following skin diseases; sarcoidosis, lupus vulgaris, lupus miliaris disseminatus faciei (LMDF), tattoo granuloma, lichen nitidus, foreign body granuloma, granuloma annulare, xanthelasma, xanthoma tuberosum, xanthoma planum, juvenile xanthogranuloma, giant cell tumor of tendon sheath, dermatofibroma, malignant fibrous histiocytoma, dermatofibrosarcoma protuberans, granulation tissue of burn, hypertrophic scar, and histiocytosis X. From both the immunohistochemical and the electron microscopic features it was concluded that a) immunohistochemically LZ-positive cells from lesions of sarcoidosis, lupus vulgaris, LMDF and tattoo granuloma had a number of electron-lucent bodies (ELB) or microvesicles in their cytoplasm, b) lichen nitidus and xanthoma tuberosum had few LZ-positive cells and the ELB were not observed, and c) the other diseases were LZ-negative, and the ELB were also absent. It is suggested that LZ is present in the ELB which are observed electron microscopically.
Assuntos
Granuloma/enzimologia , Histiócitos/enzimologia , Muramidase/análise , Dermatopatias/enzimologia , Histiócitos/ultraestrutura , Sarcoma Histiocítico/enzimologia , Histiocitoma Fibroso Benigno/enzimologia , Histiocitose de Células de Langerhans/enzimologia , Humanos , Imuno-Histoquímica , Microscopia Eletrônica , Neoplasias Cutâneas/enzimologiaRESUMO
Immunoreactive lysozyme was readily detectable in canine histiocytic disorders including systemic histiocytosis, malignant histiocytosis and granulomatous panniculitis. Lysozyme was less reliable as a histiocytic marker in cutaneous histiocytoma; forty percent of these tumors were negative for lysozyme expression. The marked heterogeneity in lysozyme expression in cutaneous histiocytoma may indicate that a proportion of these tumors show relatively primitive histiocytic differentiation and do not express lysozyme. Alternatively, this same proportion may exhibit a phenotype akin to cutaneous Langerhans cells which do not contain lysozyme. Lysozyme was not detectable in the tumor cells in lymphomatoid granulomatosis, atypical cutaneous histiocytoma, and histiocytic lymphosarcoma. Other evidence that these three disorders do not represent true histiocytic proliferative disorders is discussed.